MAYNF (Mayne Pharma Group) EBITDA per Share: $0.24 (TTM As of Dec. 2025)


MAYNF Mayne Pharma Group Ltd MAYNF
48 GF Score
Price $1.65
GF Value $3.87
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group EBITDA per Share?

Mayne Pharma Group MAYNF 48 EBITDA per Share is $0.24 as of Dec. 2025. GuruFocus rates MAYNF with a GF Score™ of 48/100 and a GF Value™ of $3.87 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 105 Medical Distribution companies, Mayne Pharma Group ranks worse than 952380% on this metric.

Mayne Pharma Group's EBITDA per Share for the six months ended in Dec. 2025 was $0.34. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.24.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Mayne Pharma Group's EBITDA per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Mayne Pharma Group was 64.90% per year. The lowest was -103.90% per year. And the median was 19.30% per year.

MAYNF's 3-Year EBITDA Growth Rate is not ranked *
in the Medical Distribution industry.
Industry Median: 5.5
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Mayne Pharma Group's EBITDA for the six months ended in Dec. 2025 was $27.9 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Mayne Pharma Group was 102.00% per year. The lowest was -109.00% per year. And the median was 24.40% per year.


Mayne Pharma Group  (OTCPK:MAYNF) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Mayne Pharma Group EBITDA per Share Related Terms


Mayne Pharma Group EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Mayne Pharma Group's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group EBITDA per Share Chart

Mayne Pharma Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.59 -0.89 -1.43 -0.73 0.21

Mayne Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -0.58 0.30 -0.11 0.34
MAYNF
48GF Score
Mayne Pharma Group Ltd MAYNF
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mayne Pharma Group EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Mayne Pharma Group's EBITDA per Share for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA per Share(A: Jun. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=16.49/79.139
=0.21

Mayne Pharma Group's EBITDA per Share for the quarter that ended in Dec. 2025 is calculated as

EBITDA per Share(Q: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=27.857/81.246
=0.34

EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of $0.24 mean?
Mayne Pharma Group (MAYNF) has a EBITDA per Share of $0.24 as of Dec. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #999999 out of 105 companies in the Medical Distribution industry.
Is Mayne Pharma Group's EBITDA per Share too high?
Mayne Pharma Group's current EBITDA per Share is $0.24. The Medical Distribution industry median EBITDA per Share is 5.50. Mayne Pharma Group's value of $0.24 is 95.6% below this industry median. Based on the distribution chart, Mayne Pharma Group ranks #999999 out of 105 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's EBITDA per Share compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #999999 out of 105 companies for EBITDA per Share. This places Mayne Pharma Group in the lower half of its industry. The industry median EBITDA per Share is 5.50. Mayne Pharma Group's value of $0.24 is 95.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Medical Distribution company?
The median EBITDA per Share among Medical Distribution companies is 5.50, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayne Pharma Group's current EBITDA per Share of $0.24 is 95.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median EBITDA per Share is 5.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current EBITDA per Share is $0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.87, compared to a current price of $1.65 — trading 57.4% below its estimated fair value. The current EBITDA per Share is $0.24 and 95.6% below the Medical Distribution industry median of 5.50. Mayne Pharma Group's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current EBITDA per Share is $0.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mayne Pharma Group (MAYNF) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of $1.65 is trading 57.4% below its estimated GF Value™ of $3.87. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for MAYNF:

  • EBITDA per Share: $0.24
  • GF Value™: $3.87 vs. price of $1.65 (57.4% below fair value)
  • GF Score™: 48/100 with 3 warning signs
  • Industry Position: 95.6% below the Medical Distribution median (#999999 of 105)

No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mayne Pharma Group Business Description

Other Exchanges MYX:Australia
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
48GF Score

Get the complete analysis for MAYNF

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price
$3.87
GF Value